Human amyloid-β synthesis and clearance rates as measured in cerebrospinal fluid in vivo
Open accessThe DOI matches its Crossref record; 40 of the 41 references it cites were found in a registry or an index.
Abstract
Certain disease states are characterized by disturbances in production, accumulation or clearance of protein. In Alzheimer disease, accumulation of amyloid-beta (Abeta) in the brain and disease-causing mutations in amyloid precursor protein or in enzymes that produce Abeta indicate dysregulation of production or clearance of Abeta. Whether dysregulation of Abeta synthesis or clearance causes the most common form of Alzheimer disease (sporadic, >99% of cases), however, is not known. Here, we describe a method to determine the production and clearance rates of proteins within the human central nervous system (CNS). We report the first measurements of the fractional production and clearance rates of Abeta in vivo in the human CNS to be 7.6% per hour and 8.3% per hour, respectively. This method may be used to search for novel biomarkers of disease, to assess underlying differences in protein metabolism that contribute to disease and to evaluate treatments in terms of their pharmacodynamic effects on proposed disease-causing pathways.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In non-pathological conditions the clearance of cerebral Aβ exceeds its production [9].”
From PCSK9 acts as a key regulator of Aβ clearance across the blood–brain barrier (2022) · cites this paper as [9]
In the citing paper
“we adapted an in vivo stable isotopic labeling kinetics technique previously described in humans (43).”
From Human ApoE isoforms differentially regulate brain amyloid-β peptide clearance (2011) · cites this paper as [43]
In the citing paper
“which is approximately 4-times slower than the turnover rate for the total CNS Aβ peptide (Fig. 6) [31]”
From In Vivo Human Apolipoprotein E Isoform Fractional Turnover Rates in the CNS (2012) · cites this paper as [31]
In the citing paper
“The interstitial concentration of Aβ is higher in awake than in sleeping rodents and humans”
From Sleep Drives Metabolite Clearance from the Adult Brain (2013) · cites this paper as [15]
In the citing paper
“In prior SILK studies (19), plasma 13C6-leucine enrichment was found to adequately represent 13C6 labeling in the precursor pool for Aβ synthesis.”
From An Antidepressant Decreases CSF Aβ Production in Healthy Individuals and in Transgenic AD Mice (2014) · cites this paper as [19]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease
Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., et al. (1997) · Science · doi:10.1126/science.276.5321.2045 · Cited by 8,240
Alzheimer's Disease: Genes, Proteins, and Therapy
Selkoe, D. J. (2001) · Physiological Reviews · doi:10.1152/physrev.2001.81.2.741 · Cited by 6,063
Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17
Hutton, M., Lendon, C. L., Rizzu, P., Baker, M., Froelich, S., Houlden, H., Pickering-Brown, S., Chakraverty, S., Isaacs, A., Grover, A., et al. (1998) · Nature · doi:10.1038/31508 · Cited by 3,498
Self-citationDeMattos, R. B., Bales, K. R., Cummins, D. J., Dodart, J.-C., Paul, S. M., & Holtzman, D. M. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.151261398 · Cited by 1,298 · cited 1×
“Several earlier studies have shown that some plasma Aβ can enter the CN”
BackgroundSelf-citationOccurrence of neuropathological changes and dementia of Alzheimer’s disease in Down’s syndrome
Wisniewski, K. E., Wisniewski, H. M., & Wen, G. Y. (1985) · Annals of Neurology · doi:10.1002/ana.410170310 · Cited by 1,159 · cited 1×
“In Down syndrome, three copies of APP result in increased production of Aβ, and 100% of individuals with Down syndrome develop Alzheimer disease pathology by age 35 (ref”
Garlick, P. J., McNurlan, M. A., & Preedy, V. R. (1980) · Biochemical Journal · doi:10.1042/bj1920719 · Cited by 973
Amyloid β Protein (Aβ) in Alzheimeri's Disease Brain
Gravina, S. A., Ho, L., Eckman, C. B., Long, K. E., Otvos, L., Younkin, L. H., Suzuki, N., & Younkin, S. G. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.13.7013 · Cited by 676
Cerebrospinal Fluid in Diseases of the Nervous System.
(1980) · Annals of Internal Medicine · doi:10.7326/0003-4819-93-3-517_1 · Cited by 657
Water-soluble Aβ(N-40, N-42) oligomers in normal and Alzheimer disease brains
Kuo, Y.-M., Emmerling, M. R., Vigo-Pelfrey, C., Kasunic, T. C., Kirkpatrick, J. B., Murdoch, G. H., Ball, M. J., & Roher, A. E. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.8.4077 · Cited by 618
Cited by
Items 401–500 of 627
Petrovskaya, A. V., Tverskoi, A. M., Barykin, E. P., Varshavskaya, K. B., Dalina, A. A., Mitkevich, V. A., Makarov, A. А., & Petrushanko, I. Y. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms24010183 · Cited by 11
Lefebvre, C., Vreulx, A.-C., Dumortier, C., Bégard, S., Gelle, C., Siedlecki‐Wullich, D., Colin, M., Kilinc, D., & Halliez, S. (2024) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.3c00997 · Cited by 10
Schneider, T. R., Stöckli, L., Felbecker, A., & Nirmalraj, P. N. (2024) · Brain Communications · doi:10.1093/braincomms/fcae180 · Cited by 10
Vestergaard, M. B., Bakhtiari, A., Osler, M., Mortensen, E. L., Lindberg, U., Law, I. G., Lauritzen, M., Benedek, K., & Larsson, H. B. W. (2025) · Alzheimer s Research & Therapy · doi:10.1186/s13195-024-01652-z · Cited by 11
Monitoring the amyloid beta-peptide in vivo – caveat emptor
Thompson, P. W., & Lockhart, A. (2009) · Drug Discovery Today · doi:10.1016/j.drudis.2008.12.004 · Cited by 12
Alzheimer’s Disease Drug Development: A Research and Development Ecosystem
Cummings, J. L., Kinney, J. W., & Fillit, H. M. (2022) · Cambridge University Press eBooks · doi:10.1017/9781108975759.002 · Cited by 10
Mazura, A. D., & Pietrzik, C. U. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15041268 · Cited by 9
Zheng, X., Yuan, W., Li, L., Ma, H., Zhu, M., Li, X., & Feng, X. (2025) · European Journal of Medical Research · doi:10.1186/s40001-025-02937-1 · Cited by 9
“The clearance of cerebral Aβ exceeds its production rate in physiological conditions [108], however, only Aβ clearance decreased accompanied by an unaffected production rate when patients suffering from AD [109].”
Basri, R., Awan, F. M., Yang, B. B., Awan, U. A., Obaid, A., Naz, A., Ikram, A., Khan, S., Haq, I. U., Khan, S. N., et al. (2023) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2022.1078441 · Cited by 9
Исаев, Н. К., Генрихс, Е. Е., & Stelmashook, E. V. (2024) · Reviews in the Neurosciences · doi:10.1515/revneuro-2024-0007 · Cited by 9
Lassman, M. E., Chappell, D. L., McAvoy, T., Cheng, A., de Alwis, D. P., Pruitt, S. K., Laterza, O., Li, C. H., Stoch, A., & Mayawala, K. (2020) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2129 · Cited by 9
Protein production is an early biomarker for RNA ‐targeted therapies
Self, W. K., Schoch, K. M., Alex, J., Barthélemy, N. R., Bollinger, J. G., Sato, C., Cole, T. A., Kordasiewicz, H. B., Swayze, E. E., Bateman, R. J., et al. (2018) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.657 · Cited by 9
Self-citationTranslational Scoring of Candidate Treatments for Alzheimer’s Disease: A Systematic Approach
Cummings, J. L. (2020) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000507569 · Cited by 10
Yu, Y., Zhang, N., Xiang, B., Ding, N., Liu, J., Huang, J., Zhao, M., Zhao, Y., Wang, Y., & Ma, Z. (2023) · Neurophotonics · doi:10.1117/1.nph.10.1.015005 · Cited by 10
Alzheimer's Disease: Definition, Molecular and Genetic Factors
Babušíková, E., Evinová, A., Jurečeková, J., Jeseňák, M., & Dobrot, D. (2011) · InTech eBooks · doi:10.5772/29027 · Cited by 9
Biomarkers for Alzheimer's disease: ready for the next step
Rosenberg, P. B., & Hillis, A. E. (2009) · Brain · doi:10.1093/brain/awp184 · Cited by 9
Using a systems-based approach to overcome reductionist strategies in the development of diagnostics
Maguire, G. (2013) · Expert Review of Molecular Diagnostics · doi:10.1586/14737159.2013.846828 · Cited by 11
Neurobiology of Alzheimer’s Disease
Wong, P. C., Savonenko, A. V., Li, T., & Price, D. L. (2012) · Elsevier eBooks · doi:10.1016/b978-0-12-374947-5.00046-8 · Cited by 12
Rest, Repair, Repeat: The Complex Relationship of Autophagy and Sleep
Ullern, H., Schnur, P., Boccara, C. N., & Knævelsrud, H. (2025) · Journal of Molecular Biology · doi:10.1016/j.jmb.2025.169227 · Cited by 10
Modelling cerebrovascular pathology and the spread of amyloid beta in Alzheimer’s disease
Ahern, A., Thompson, T., Oliveri, H., Lorthois, S., & Goriely, A. (2025) · Proceedings of the Royal Society A Mathematical Physical and Engineering Sciences · doi:10.1098/rspa.2024.0548 · Cited by 9
Cerebrospinal Fluid β-Amyloid and Dynabridging in Alzheimer's Disease Drug Development
Ereshefsky, L., Jhee, S. S., Yen, M., Moran, S., Pretorius, S., & Adams, J. (2009) · Biomarkers in Medicine · doi:10.2217/bmm.09.39 · Cited by 8
Peng, H., Noh, K., Pan, S. R., Saldivia, V., Serson, S., Toscan, A., de Lannoy, I. A. M., & Pang, K. S. (2020) · Drug Metabolism and Disposition · doi:10.1124/dmd.120.090886 · Cited by 9
Gaudreault, R., Hervé, V., van de Ven, T. G. M., Mousseau, N., & Ramassamy, C. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-201549 · Cited by 10
Cerebrospinal fluid flushing as a means of neuroprotection
Dufwenberg, M. A., Garfinkel, A., Greenhill, M. J., Garewal, A., & Larson, M. C. (2023) · Frontiers in Neuroscience · doi:10.3389/fnins.2023.1288790 · Cited by 8
Kapitanov, G., Chabot, J., Narula, J., Roy, M., Neubert, H., Palandra, J., Farrokhi, V., Johnson, J. S., Webster, R., & Jones, H. M. (2021) · Frontiers in Bioinformatics · doi:10.3389/fbinf.2021.731340 · Cited by 9
Lehmann, S., Poinot, P., Tiers, L., Junot, C., Bécher, F., & Hirtz, C. (2011) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm.2011.744 · Cited by 8
Update on amyloid‐βhomeostasis markers for sporadic Alzheimer's disease
Zetterberg, H. (2009) · Scandinavian Journal of Clinical and Laboratory Investigation · doi:10.1080/00365510802651841 · Cited by 8
Wijesinghe, P., Hosseini, A., Campbell, M., Tejpal, S., Haynes, J. R., Xi, J., Mackenzie, I. R., Hirsch‐Reinshagen, V., Hsiung, G. R., Spiller, B. W., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70592 · Cited by 8
Acute effects of lactate infusion on metabolism, AD biomarkers, and cognition: The LEAN study
Kemna, R. E., Kueck, P. J., Blankenship, A. E., John, C. S., Johnson, C. N., Green, Z. D., Mayfield, H. D., Yoksh, L., Johnson, L. A., Thyfault, J. P., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70984 · Cited by 8
Self-citationYang, C., Zhao, E., Zhang, H., Duan, L.-Q., Han, X., Ding, H., Cheng, Y., Wang, D., Lei, X., & Diwu, Y. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1508726 · Cited by 7
Mehrabian, S., Alexopoulos, P., Ortner, M., Traykov, L. D., Grimmer, T., Kurz, A., Förstl, H., Bickel, H., & Diehl‐Schmid, J. (2015) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s95018 · Cited by 7
Clinical significance of plasma candidate biomarkers of Alzheimer’s Disease
Lewczuk, P., Łukaszewicz‐Zając, M., Kornhuber, J., & Mroczko, B. (2024) · Neurologia i Neurochirurgia Polska · doi:10.5603/pjnns.100675 · Cited by 11
Combining bioinformatics and MS-based proteomics: clinical implications
Acosta‐Martin, A. E., & Lane, L. (2014) · Expert Review of Proteomics · doi:10.1586/14789450.2014.900446 · Cited by 7
Targeting apolipoprotein E for treating Alzheimer’s disease
Bales, K. R., & Paul, S. M. (2019) · Neuroscience Letters · doi:10.1016/j.neulet.2019.134366 · Cited by 8
Hark, T. J., & Savas, J. N. (2021) · Journal of Neurochemistry · doi:10.1111/jnc.15298 · Cited by 8
Fractional synthesis and clearance rates for amyloid β
Edland, S. D., & Galasko, D. R. (2011) · Nature Medicine · doi:10.1038/nm.2495 · Cited by 7
Kandi, S., Cline, E. N., Rivera, B. M., Viola, K. L., Zhu, J., Condello, C., LeDuc, R. D., Klein, W. L., Kelleher, N. L., & Patrie, S. M. (2023) · Journal of Proteome Research · doi:10.1021/acs.jproteome.3c00353 · Cited by 6
Stable isotope labelling kinetics of neurofilament light
Leckey, C. A., Giovannucci, T. A., Coulton, J. B., He, Y., Sato, C., Ghoshal, N., Vignarajah, T., Jaunmuktane, Z., Barthélemy, N. R., Zetterberg, H., et al. (2025) · Brain Communications · doi:10.1093/braincomms/fcaf468 · Cited by 7
Self-citationKuller, L. H. (2020) · Journal of clinical lipidology · doi:10.1016/j.jacl.2020.12.011 · Cited by 7
Patil, S. P., & Kuehn, B. R. (2024) · Pharmaceuticals · doi:10.3390/ph17040491 · Cited by 7
Clinical Trials for Disease‐Modifying Drugs Such as BACE Inhibitors
Hsu, H. H. (2010) · Wiley eBooks · doi:10.1002/9780470594087.ch9 · Cited by 6
Dose ranging for trials through biomarkers of drug effects
Potter, W. Z. (2010) · The journal of nutrition health & aging · doi:10.1007/s12603-010-0070-5 · Cited by 6
Hata, S., Hu, A., Piao, Y., Nakaya, T., Taru, H., Morishima‐Kawashima, M., Murayama, S., Nishimura, M., & Suzuki, T. (2019) · Human Molecular Genetics · doi:10.1093/hmg/ddz297 · Cited by 6
Kuller, L. H., Snitz, B. E., Hughes, T. M., Chang, Y., Cohen, A. D., Mathis, C. A., Aizenstein, H. J., & López, O. L. (2022) · Alzheimer s & Dementia · doi:10.1002/alz.12493 · Cited by 6
Public Health Research Priorities For The Future
Ness, R. B. (2011) · Public health reviews · doi:10.1007/bf03391629 · Cited by 6
Yang, H., Inglis, B., Talavage, T. M., Nair, V. V., Yao, J. (., Fitzgerald, B., Schwichtenberg, A. J., & Tong, Y. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.03.29.437406 · Cited by 8
Editorial: Beta Amyloid: From Physiology to Pathogenesis
Nichols, R. A., Gulisano, W., & Puzzo, D. (2022) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2022.876224 · Cited by 8
Mukherjee, S., Coyle, R. A., Dubois, C., Perez, K. A., McLean, C., Masters, C. L., & Roberts, B. R. (2025) · Acta Neuropathologica · doi:10.1007/s00401-025-02914-2 · Cited by 9
The roles of biomarkers in Alzheimer's disease clinical trials
Cummings, J. L., Sharma, S., DeAndrea, G., Osse, A. M. L., & Ortiz, A. A. (2025) · Neurotherapeutics · doi:10.1016/j.neurot.2025.e00811 · Cited by 5
Semyachkina-Glushkovskaya, O. V., Sursaev, V. A., Poluektov, M. G., Diduk, S., Rychkova, L., Михайловна, М. И., Yakubova, L., & Kurths, J. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27052312 · Cited by 5
Tall, M. L., Lehmann, S., Diouf, E., Gérard, C., Filali, S., Gabelle, A., Hirtz, C., Gabert, L., Sauvinet, V., Pirot, F., et al. (2014) · Annales Pharmaceutiques Françaises · doi:10.1016/j.pharma.2014.06.002 · Cited by 5
Yang, J., Zhang, X., Duan, L., Cheng, R., Yang, N., Peng, Z., Li, B., Xu, L., Chen, W., Chen, J., et al. (2025) · Frontiers in Nutrition · doi:10.3389/fnut.2025.1532080 · Cited by 5
Ovod, V., Scott, E. A., Flake, M. M., Parker, S. R., Bateman, R. J., & Elbert, D. L. (2011) · Journal of Biomedical Materials Research Part A · doi:10.1002/jbm.a.33285 · Cited by 5
Self-citationZhou, S., & Sun, X. (2012) · PubMed · Cited by 6
Plasma biomarkers in neuropsychiatric syndromes: A narrative review
Ismail, Z., Guan, D. X., Babulal, G. M., Bateman, J. R., Cantillon, M., Creese, B., D’Antonio, F., Fischer, C. E., Gatchel, J. R., Ghahremani, M., et al. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251392185 · Cited by 4
Bifurcations in coupled amyloid-β aggregation-inflammation systems
Chakrabarti, K. S., Bakhtiari, D., & Rezaei‐Ghaleh, N. (2024) · npj Systems Biology and Applications · doi:10.1038/s41540-024-00408-7 · Cited by 4
Proteases in the Nervous System
Cynis, H., Lichtenthaler, S. F., Wagner, L., & Demuth, H. (2013) · Springer eBooks · doi:10.1007/978-3-7091-0885-7_10 · Cited by 4
Xie, F., Emery, M. G., Gibbs, J. P., Rock, D. A., & Rock, B. M. (2016) · Bioanalysis · doi:10.4155/bio-2016-0146 · Cited by 4
Chen, X., Farrokhi, V., Singh, P., Ocaña, M. F., Patel, J. R., Lin, L., Neubert, H., & Brodfuehrer, J. (2017) · mAbs · doi:10.1080/19420862.2017.1398873 · Cited by 4
Aβ Imaging in Aging, Alzheimer’s Disease and Other Neurodegenerative Conditions
Villemagne, V. L., Fodero‐Tavoletti, M. T., Yates, P. A., Masters, C. L., & Rowe, C. C. (2014) · Springer eBooks · doi:10.1007/978-3-642-54307-4_10 · Cited by 4
Symptomatic Cognitive Enhancing Agents
Cummings, J. L., & Zhong, K. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802173-6.00017-4 · Cited by 5
Kuai, Z., Xu, Y., Zhao, Q., Liu, J., Guan, S., Qiao, Y., Gong, X., Nie, J., Li, P., Liu, D., et al. (2018) · Journal of Cellular Biochemistry · doi:10.1002/jcb.26744 · Cited by 5
Insight into the histidine tautomerism effect on heterodimers of Aβ40
Li, H., Salimi, A., Burnea, F. K. B., Shi, H., & Lee, J. Y. (2021) · Bulletin of the Korean Chemical Society · doi:10.1002/bkcs.12399 · Cited by 4
Carroll, C. M., & Benca, R. M. (2024) · Biomolecules · doi:10.3390/biom14030274 · Cited by 5
Giroux, P., Vialaret, J., Kindermans, J., Gabelle, A., Bauchet, L., Hirtz, C., Lehmann, S., & Colinge, J. (2024) · Journal of Proteome Research · doi:10.1021/acs.jproteome.4c00059 · Cited by 4
St. Jude's Children's Research Hospital
Bradford, C. (2011) · SPARK Scholarship at Parkland (Parkland College) · Cited by 4
Bereman, M. S., Tomazela, D. M., Heins, H. B., Simonato, M., Cogo, P. E., Hamvas, A., Patterson, B. W., Cole, F. S., & MacCoss, M. J. (2012) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-012-5953-3 · Cited by 4
Emerging Role of the Cerebrospinal Fluid – Neuronal Interface in Neuropathology
Ochoa, V., Loeffler, A. J., & Fowler, C. D. (2015) · Neuro - Open Journal · doi:10.17140/noj-2-118 · Cited by 4
Reply to: Fractional synthesis and clearance rates for amyloid β
Elbert, D. L., Patterson, B. W., Ercole, L., Ovod, V., Kasten, T., Mawuenyega, K., Yarasheski, K., Morris, J. C., Benzinger, T., Holtzman, D. M., et al. (2011) · Nature Medicine · doi:10.1038/nm.2496 · Cited by 3
Self-citationXu, C., Xu, E., Xiao, Y., Yang, D., Wu, G., & Chen, M. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.142887 · Cited by 5
Amyloid-β clearance: an astrocytic perspective
Li, J., Lv, Z., Chen, X. P., Fu, F., Yang, K., Lai, G., Wu, H., & Xie, G. (2026) · Frontiers in Neuroscience · doi:10.3389/fnins.2026.1812081 · Cited by 3
Huang, B., & Tang, G. (2026) · Pathology - Research and Practice · doi:10.1016/j.prp.2026.156564 · Cited by 3
Gogu, P., Bharti, J., Yadav, J. P., Grishina, M., Verma, A., Kumar, V., Singh, A. K., Verma, A., Kumar, P., Khalilullah, H., et al. (2025) · Brain Behavior & Immunity - Health · doi:10.1016/j.bbih.2025.101061 · Cited by 5
Haug, K. G., Staab, A., Dansirikul, C., & Lehr, T. (2013) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.91 · Cited by 3
Immunological Aspects and Anti-Amyloid Strategy for Alzheimer’s Dementia
Liščić, R. M. (2013) · Archives of Industrial Hygiene and Toxicology · doi:10.2478/10004-1254-64-2013-2414 · Cited by 3
Stable Isotope Labeling Kinetics in CNS Translational Medicine: Introduction to SILK Technology
Bateman, R. J., West, T., Yarasheski, K. E., Patterson, B. W., Lucey, B. P., Cirrito, J. R., Lehmann, S., Hirtz, C., Gabelle, A., Miller, T. M., et al. (2019) · Handbook of behavioral neuroscience · doi:10.1016/b978-0-12-803161-2.00011-4 · Cited by 4
Self-citationZakaria, J. A. D., Bateman, R. J., Lysakowska, M., Khatri, A. W., Jean-Gilles, D., Kennedy, M. E., & Vassar, R. J. (2022) · Scientific Reports · doi:10.1038/s41598-022-18869-3 · Cited by 4
Self-citationWan, H. I., Hurko, O., Day, M., & Rutkowski, J. L. (2009) · Drug Development Research · doi:10.1002/ddr.20292 · Cited by 4
Davis, A. E. (2012) · Wiley eBooks · doi:10.1002/9781118704950.ch6 · Cited by 3
Biomarkers of Disorders of the Nervous System
Jain, K. K. (2017) · Springer eBooks · doi:10.1007/978-1-4939-7431-3_14 · Cited by 4
Testing a test for Alzheimer disease
Bateman, R. J., & Eidelberg, D. (2007) · Neurology · doi:10.1212/01.wnl.0000257671.88772.f1 · Cited by 4
Self-citationSearching Heterocyclic Scaffolds Used to Treat Alzheimer’s Disease: A Review
Kale, M. A., & Faisal, M. (2024) · Current Drug Research Reviews · doi:10.2174/0125899775290026240612104933 · Cited by 2
The Glymphatic System, Sleep, and Neurodegeneration
Gorbachevskii, A. V., Kicherova, O. A., & Рейхерт, Л. И. (2024) · Neuroscience and Behavioral Physiology · doi:10.1007/s11055-024-01734-3 · Cited by 8
Li, B., Li, H., Chen, H., Sui, Y., Zeng, J., Lin, X., Fan, Q., & Song, Z. (2025) · Physiological Research · doi:10.33549/physiolres.935447 · Cited by 3
Lee, H. N., Han, C. W., Jeong, M. S., & Jang, S. B. (2025) · Biochemical Pharmacology · doi:10.1016/j.bcp.2025.117201 · Cited by 2
Kinetic Model with Feedback Cycle for Age-Dependent Amyloid Beta Accumulation in Mice
Tyng, V., & Kellman, M. E. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26188803 · Cited by 2
Lai, X., Xu, H., Chen, X., Ke, J., & Lin, S. (2025) · Chinese Chemical Letters · doi:10.1016/j.cclet.2025.111932 · Cited by 2
Time-of-day and age-related patterns in cerebrospinal fluid glucose and protein
Koleske, J. P., Pan, S., Meehan, T., Loe, M. E., Morales, D. M., Lucey, B. P., Musiek, E. S., & Strahle, J. M. (2025) · Fluids and Barriers of the CNS · doi:10.1186/s12987-025-00686-1 · Cited by 2
Ulku, I., Ansari, F. E., Hancock, M. A., Zhou, H., Cagnone, G., Joyal, J., Fisher, T. A. J., Kennedy, T. E., Liebsch, F., & Multhaup, G. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2507450122 · Cited by 2
Riedel, C. S., Milan, J. B., Jørgensen, N. R., Jennum, P., & Juhler, M. (2026) · Journal of Sleep Research · doi:10.1111/jsr.70292 · Cited by 4
Synapse-associated neuropathological markers in Alzheimer's disease
Barrantes, F. J. (2026) · Brain · doi:10.1093/brain/awag117 · Cited by 2
Pathological Validation of Animal Models of Dementia
Pirici, D. N., Broeckhoven, C. V., & Kumar‐Singh, S. (2010) · Neuromethods · doi:10.1007/978-1-60761-898-0_7 · Cited by 2
Salnikov, E. S., Drung, B., Fabre, G., Itkin, A., Otyepka, M., Dencher, N. A., Schmidt, B., Hauß, T., Trouillas, P., & Bechinger, B. (2018) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2018.09.003 · Cited by 2
Aβ Imaging in Aging, Alzheimer’s Disease, and Other Neurodegenerative Conditions
Villemagne, V. L., Doré, V., Burnham, S. C., & Rowe, C. C. (2020) · Springer eBooks · doi:10.1007/978-3-030-53168-3_10 · Cited by 2
Huang, C.-J., Ho, S.-Y., Wu, S., Wang, Y., & Dong, G. (2024) · Journal of the Taiwan Institute of Chemical Engineers · doi:10.1016/j.jtice.2024.105570 · Cited by 2
Recent updates on immunotherapy in neurodegenerative diseases
Salunkhe, J., & Ugale, R. R. (2024) · Brain Research · doi:10.1016/j.brainres.2024.149205 · Cited by 2
microRNAs Mediate Signaling Pathways in Alzheimer’s Disease: Biomarkers and Therapeutic Targets
Rezayof, A., Ghasemzadeh, Z., & Kouhkan, F. (2024) · Springer eBooks · doi:10.1007/978-3-030-80662-0_39 · Cited by 2
Parida, R., Rafiq, F., Chatterjee, S., Salimi, A., & Lee, J. Y. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.144098 · Cited by 2
The Framework for an Integrative Theory of Alzheimer’s Disease
Zaretsky, D. V., & Zaretskaia, M. V. (2025) · Current Alzheimer Research · doi:10.2174/0115672050381553250425062803 · Cited by 2
Donepezil and galanin interactions in an animal model of Alzheimer’s disease
Sabbagh, J. J. (2010) · Digital Scholarship - UNLV (University of Nevada Reno) · doi:10.34917/2044134 · Cited by 2
Metadata
- Authors
- Bateman, R. J., Munsell, L. Y., Morris, J. C., Swarm, R., Yarasheski, K. E., & Holtzman, D. M.
- Affiliations
- Washington University in St. Louis (US)
- Corresponding author
- Bateman, Randall J
- Venue
- Nature Medicine
- Published
- 2006-06-25
- Volume
- 12
- Issue
- 7
- Pages
- 856-861
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- PMC
- PMC2983090
- OpenAlex
- W2171259749
- Cited by
- 599
- References
- 41
- Citations by year
- 2026: 15 · 2025: 32 · 2024: 33 · 2023: 27 · 2022: 19 · 2021: 28 · 2020: 38 · 2019: 34 · 2018: 23 · 2017: 35 · 2016: 36 · 2015: 40 · 2014: 31 · 2013: 30 · 2012: 40
- FWCI
- 16.79
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Eli Lilly and Company
- American Academy of Neurology
- National Institutes of Health (5p41rr000954-34)
- National Institute on Aging (L30 AG024455, K08AG027091, P 50 AG05681, P50AG005681)
- National Institute of Diabetes and Digestive and Kidney Diseases (DK 056341, P30DK056341)
- National Center for Research Resources (P41-RR000954, RR-000954, M01-RR00036, M01RR000036)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Clinical Neurology › Cerebrospinal fluid and hydrocephalus
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- amyloid-beta, Alzheimer's disease, cerebrospinal fluid, amyloid precursor protein, biomarkers
- MeSH terms
- Amino Acid Sequence, Humans, Models, Molecular, Molecular Sequence Data, Protein Conformation, Biomarkers, Amyloid beta-Peptides
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.